Abcam, the bioscience company that markets antibodies via its market leading online catalogue, announced ahead of its AGM today that trading for the first four months of its financial year (June-October) was in line with management expectations. Demand for the company's products was strong, with some benefit being derived from Sterling weakness. So far, sales have not been affected by expected cutbacks in publicly funded health research programmes (which represent a significant portion of Abcam sales). However, Abcam warned that because of the pressure to reduce deficits, Western governments may cut research projects which could, in turn, affect Abcam's sales.

During the AGM, shareholders approved a five for one stock split of Abcam's ordinary shares. The split is expected to become effective on the 15 November 2010.

Unlock the rest of this article with a 14 day trial

Unlock with Email
Unlock with Google

Already have an account?
Login here